
SOTIO Appoints New Chief Scientific and Development Officers
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, announced two key executive appointments aimed at accelerating the development of its growing pipeline of novel antibody-drug conjugates (ADCs) and immunotherapies designed to treat difficult-to-manage solid tumors. The company has…


